NASDAQ$IOVA
Iovance Biotherapeutics Inc. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Iovance reported Q2 2024 earnings with strong Amtagvi launch momentum.
Iovance Biotherapeutics reported a revenue of $31.1 million for Q2 2024, driven by the launch of Amtagvi and continued Proleukin sales. The company's cash position as of July 24, 2024, is approximately $449.6 million, expected to fund operations into early 2026.
- Total revenue for Q2 2024 was $31.1 million, including Amtagvi and Proleukin sales.
- Amtagvi generated $12.8 million in revenue from completed infusions during Q2 2024.
- Net loss for Q2 2024 was $97.1 million, or $0.34 per share.
- Cash position as of July 24, 2024, was approximately $449.6 million.
Headline financials
Revenue & EPS history
Iovance · Revenue · Quarterly
$31.1M
Forward guidance
Iovance anticipates continued growth in Amtagvi demand and expects this growth to continue into 2025, 2026 and beyond. They provided product revenue guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25.
Tailwinds
- Amtagvi and Proleukin demand remains strong and continues to increase.
- ATC network expansion is expected to accelerate quarterly growth.
- Company is expanding its global commercial footprint.
- Company is expanding its proprietary manufacturing capabilities.
- Company has a broad clinical pipeline.
Headwinds
- Risks related to successful commercialization of products.
- Risks related to market acceptance of products.
- Risks related to ability to manufacture therapies.
- Risks related to timing and ability to develop product candidates.
- Effects of global and domestic geopolitical factors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-1.0%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-1.2%
Avg return
30 days after
37%
20 / 54 earnings
Positive
+36.3%
Q4 2019
Best reaction
-45.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.2% | -12.7% | +3.4% | |
| Q4 2025 | +30.1% | +33.6% | +27.7% | |
| Q3 2025 | +27.9% | +46.4% | +21.5% | |
| Q1 2025 | -45.1% | -46.1% | -35.3% | |
| Q4 2024 | -19.4% | -23.0% | -32.3% | |
| Q3 2024 | -12.8% | -20.2% | -25.6% | |
| Q2 2024 | +35.3% | +46.5% | +36.6% | |
| Q1 2024 | -18.1% | -19.9% | -41.9% | |
| Q4 2023 | -8.9% | +72.3% | +67.9% | |
| Q3 2023 | -3.5% | -8.1% | +55.8% | |
| Q2 2023 | +7.8% | +0.1% | -17.7% | |
| Q1 2023 | +7.9% | +5.5% | +13.0% | |
| Q4 2022 | +1.8% | +2.5% | -14.2% | |
| Q3 2022 | +0.0% | -7.0% | -23.1% | |
| Q2 2022 | +1.2% | -0.2% | -8.8% | |
| Q1 2022 | -12.4% | -17.2% | -52.4% | |
| Q4 2021 | +10.2% | +9.4% | +20.5% | |
| Q3 2021 | +0.6% | -0.2% | -33.4% | |
| Q2 2021 | +3.2% | +2.1% | +10.1% | |
| Q1 2021 | -2.4% | -9.3% | -38.7% | |
| Q4 2020 | -5.4% | -5.3% | -27.3% | |
| Q3 2020 | +2.2% | -3.7% | +8.9% | |
| Q2 2020 | -5.3% | -8.8% | -0.7% | |
| Q1 2020 | +1.2% | +12.0% | -4.3% | |
| Q4 2019 | +36.3% | +33.3% | +29.4% | |
| Q3 2019 | -0.7% | +7.5% | +12.5% | |
| Q2 2019 | -3.5% | -8.6% | -14.6% | |
| Q1 2019 | -5.5% | -3.2% | +61.2% | |
| Q4 2018 | -1.7% | +7.8% | -9.0% | |
| Q3 2018 | -3.2% | -5.1% | +5.3% | |
| Q2 2018 | +6.9% | +6.5% | +23.3% | |
| Q1 2018 | +0.7% | +1.0% | -16.2% | |
| Q4 2017 | -8.6% | -11.8% | -21.2% | |
| Q3 2017 | -6.5% | +2.0% | +18.3% | |
| Q2 2017 | -5.1% | -4.3% | -1.7% | |
| Q1 2017 | -9.8% | -11.7% | -24.8% | |
| Q4 2016 | -1.3% | +2.7% | -10.1% | |
| Q3 2016 | +5.1% | +19.7% | +2.6% | |
| Q2 2016 | -2.1% | -1.5% | -11.1% | |
| Q1 2016 | +4.4% | — | — | |
| Q4 2015 | -5.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q4 2014 | +18.7% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q2 2013 | -2.8% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -20.0% | — | — | |
| Q2 2012 | -26.0% | — | — | |
| Q1 2012 | +2.6% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | -0.8% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +6.1% | — | — | |
| Q4 2010 | +0.0% | — | — | |
| Q3 2010 | -4.5% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro